Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Open Access Macedonian Journal of Medical Sciences ; 10(C):257-260, 2022.
Article in English | EMBASE | ID: covidwho-2066672

ABSTRACT

BACKGROUND: Psoriasis is a chronic inflammatory disease that affects 2% of population. About 0.5–2% of psoriatic cases develop during pediatric age. In most cases, the condition is responsive to topical treatment. However, a small percentage of children require systemic treatment with conventional systemic drugs or biological agents, such as anti-tumor necrosis factor (TNF)-α. Adalimumab (ADA) is an anti-TNF-α recently approved for pediatric psoriasis in the European Union (from 4 years of age, 2015). CASE PRESENTATION: We describe our experience treating a 5-year-old female patient affected by severe plaque psoriasis with ADA biosimilar during SARS-CoV-2 pandemic outbreak also using teledermatology. CONCLUSION: The case reported in this article highlights the safety and the effectiveness of ADA biosimilar MSB11022 (Idacio®) in the treatment of a 5-year-old female affected by plaque psoriasis and paves the way to bigger trials for a more extensive use of TNF-α inhibitor biosimilars for psoriasis in pediatric population.

2.
Journal of Investigative Dermatology ; 142(8, Supplement):B38, 2022.
Article in English | ScienceDirect | ID: covidwho-1936828
5.
J Eur Acad Dermatol Venereol ; 36(9): e678-e680, 2022 09.
Article in English | MEDLINE | ID: covidwho-1861407
6.
J Eur Acad Dermatol Venereol ; 36(8): 1292-1299, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1807159

ABSTRACT

BACKGROUND: Moderate-to-severe atopic dermatitis (AD) in the adolescence is a high burden disease, and its treatment can be very challenging due to paucity of approved systemic drugs for this age and their side-effects. Dupilumab was recently approved for treatment of adolescent AD. OBJECTIVES: A multicentre, prospective, real-world study on the effectiveness and safety of dupilumab in adolescents (aged from ≥12 to <18 years) with moderate-to-severe AD was conducted. The main AD clinical phenotypes were also examined. METHODS: Data of adolescents with moderate-to-severe AD treated with dupilumab at label dosage for 16 weeks were collected. Treatment outcome was assessed by EASI, NRS itch, NRS sleep loss and CDLQI scores at baseline and after 16 weeks of treatment. The clinical scores were also evaluated according to clinical phenotypes. RESULTS: One hundred and thirty-nine adolescents were enrolled in the study. Flexural eczema and head and neck eczema were the most frequent clinical phenotypes, followed by hand eczema and portrait-like dermatitis. Coexistence of more than 1 phenotype was documented in 126/139 (88.5%) adolescents. Three patients (2.1%) contracted asymptomatic SARS-CoV-2 infection and 1 of the discontinued dupilumab treatment before the target treatment period. A significant improvement in EASI, NRS itch, NRS sleep loss and CDLQI was observed after 16 weeks of treatment with dupilumab. This outcome was better than that observed in clinical trials. Dupilumab resulted effective in all AD phenotypes, especially in diffuse eczema. Twenty-eight (20.1%) patients reported adverse events, conjunctivitis and flushing being the most frequent. None of patients discontinued dupilumab due to adverse event. CONCLUSIONS: Dupilumab in adolescent AD showed excellent effectiveness at week 16 with consistent improvement of all clinical scores. Moreover, dupilumab showed a good safety profile also in this COVID-19 pandemic era.


Subject(s)
COVID-19 , Dermatitis, Atopic , Eczema , Antibodies, Monoclonal, Humanized , COVID-19/drug therapy , Dermatitis, Atopic/drug therapy , Double-Blind Method , Humans , Pandemics , Prospective Studies , Pruritus , SARS-CoV-2 , Severity of Illness Index , Treatment Outcome
10.
J Eur Acad Dermatol Venereol ; 35(12): e845-e846, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1345982
11.
J Eur Acad Dermatol Venereol ; 35(11): e745-e747, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1325020
13.
SELECTION OF CITATIONS
SEARCH DETAIL